Vemurafenib for treating resected BRAF V600 mutation-positive melanoma [ID1250]
Discontinued
Reference number: GID-TA10213
The company have advised that they will not be pursuing a licensing application for vemurafenib from the European Medicines Authority for this indication at this time. Therefore, NICE has decided to suspend this appraisal on its work programme.